Loading Alivus Life Sciences…
| ₹ Cr | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue | 640 | 689 | 673 | 602 | 650 |
| Operating profit | 191 | 194 | 212 | 155 | 182 |
| Operating margin | 29.8% | 28.2% | 31.4% | 25.8% | 28.1% |
| Net profit | 160 | 163 | 150 | 122 | 142 |
| Net margin | 25.0% | 23.6% | 22.3% | 20.2% | 21.8% |
| EPS (₹) | 13.01 | 13.22 | 12.22 | 9.88 | 11.55 |
Quarters are labelled by period end.
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 2,504 | 2,340 | 2,185 | 2,048 |
| Operating profit | 722 | 624 | 622 | 601 |
| Operating margin | 28.9% | 26.7% | 28.5% | 29.3% |
| Net profit | 564 | 486 | 471 | 467 |
| Net margin | 22.5% | 20.8% | 21.6% | 22.8% |
| EPS (₹) | 45.90 | 39.52 | 38.38 | 38.11 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Total assets | 3,983 | 3,411 | 2,850 | 2,702 |
| Total liabilities | 651 | 594 | 518 | 564 |
| Shareholders’ equity | 3,332 | 2,817 | 2,332 | 2,138 |
| Total debt | 57 | 57 | 17 | 19 |
| Cash & equivalents | 2 | 71 | 301 | 284 |
| Debt / equity | 0.02 | 0.02 | 0.01 | 0.01 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Operating cash flow | 565 | 392 | 414 | 306 |
| Capital expenditure | -307 | -166 | -129 | -163 |
| Free cash flow | 258 | 225 | 285 | 143 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Return on equity | 16.9% | 17.2% | 20.2% | 21.8% |
| Return on assets | 14.2% | 14.2% | 16.5% | 17.3% |
| Net margin | 22.5% | 20.8% | 21.6% | 22.8% |
Source: Yahoo Finance. Figures in ₹ crore unless stated.
No analyst data available for ALIVUS. Finnhub coverage is limited for some India-listed stocks.